四联药物治疗幽门螺杆菌感染慢性胃炎安全性及疗效分析

摘要

目的:分析四联药物治疗幽门螺杆菌感染慢性胃炎安全性及疗效.方法:将150例幽门螺杆菌感染慢性胃炎患者按治疗方法不同分为A,B,C 3组.均给予雷贝拉唑、胶体铋剂、克拉霉素.A组另增加阿莫西林,B组另增加甲硝唑.比较3组治疗总有效率、症状及溃疡消失率、幽门螺杆菌清除率.观察不良反应.结果:A组治疗总有效率(92.00%)最高,B组(86.00%)高于C组;A组消化道症状消失率(90.00%)、溃疡消失率(94.00%)以及幽门螺杆菌根除率(92.00%)均为最高,B组高于C组(P<0.05).均无明显不良反应.结论:四联药物治疗幽门螺杆菌疗效较三联药物疗效强,无明显不良反应,含铋剂四联疗法中阿莫西林的效果较甲硝唑优.%Objective:To analyze the safety and efficacy of treatment of chronic gastritis with Helicobacter pylori infection by quadruple drugs therapy.Methods:150 cases of chronic gastritis patients with Helicobacter pylori infection were divided into 3 groups according to treatment methods.Rebela,colloidal bismuth agent, and clarithromycin were administered to the 3 groups.On the basis of the medication, group A was added with amoxicillin and group B with metronidazole.Comparison was conducted in terms of the total effective rate, disappearance rate of symptoms and ulcer, and eradication rate of Helicobacter pylori.Meanwhile, adverse reactions were observed.Results:The total effective rate of group A (92%), and group B (86%) was higher than that of group C.As for group A, the gastrointestinal symptoms disappearance rate (90%), the ulcer disappearance rate (94%) and Helicobacter pylori eradication rate (92%) were the highest among the 3 groups,and group B was higher than group C in terms of the rates(P<0.05).No obvious adverse reactions occurred in the 3 groups.Conclusion:Quadruple drugs therapy in treatment of Helicobacter pylori infection is more effective than triple drugs therapy.No obvious adverse reactions are observed.